Top 5 Stocks to Buy Now
→ SpaceX is offering you shares. Don't take them. (From Behind the Markets) (Ad)tc pixel Free CREO Stock Alerts

Creo Medical Group (CREO) Competitors

Creo Medical Group logo
GBX 13.50 -0.25 (-1.82%)
As of 12:10 PM Eastern
Compare

CREO vs. NIOX, EKF, IUG, NCYT, and IHC

Should you buy Creo Medical Group stock or one of its competitors? MarketBeat compares Creo Medical Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Creo Medical Group include NIOX Group (NIOX), EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), and Inspiration Healthcare Group (IHC). These companies are all part of the "medical devices" industry.

How does Creo Medical Group compare to NIOX Group?

Creo Medical Group (LON:CREO) and NIOX Group (LON:NIOX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Creo Medical Group presently has a consensus target price of GBX 40, indicating a potential upside of 196.30%. NIOX Group has a consensus target price of GBX 86, indicating a potential upside of 52.48%. Given Creo Medical Group's higher probable upside, analysts clearly believe Creo Medical Group is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Creo Medical Group has a beta of 1.6246382, indicating that its share price is 62% more volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 6.4% of Creo Medical Group shares are held by insiders. Comparatively, 5.1% of NIOX Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NIOX Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.93-£25.04M£1.0013.50
NIOX Group£48.70M4.87£995.88M£1.6434.39

Creo Medical Group has a net margin of 88.33% compared to NIOX Group's net margin of 14.37%. NIOX Group's return on equity of 10.14% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
NIOX Group 14.37%10.14%3.95%

In the previous week, Creo Medical Group's average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company Overall Sentiment
Creo Medical Group Neutral
NIOX Group Neutral

Summary

NIOX Group beats Creo Medical Group on 8 of the 14 factors compared between the two stocks.

How does Creo Medical Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

EKF Diagnostics has a beta of 0.516, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.6246382, indicating that its stock price is 62% more volatile than the broader market.

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 39.9% of EKF Diagnostics shares are owned by insiders. Comparatively, 6.4% of Creo Medical Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.24£4.68M£0.4757.02
Creo Medical Group£6M10.93-£25.04M£1.0013.50

EKF Diagnostics presently has a consensus price target of GBX 35, suggesting a potential upside of 30.60%. Creo Medical Group has a consensus price target of GBX 40, suggesting a potential upside of 196.30%. Given Creo Medical Group's higher probable upside, analysts plainly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.12%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Creo Medical Group 88.33%9.56%-20.09%

In the previous week, EKF Diagnostics' average media sentiment score of 0.75 beat Creo Medical Group's score of 0.00 indicating that EKF Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
EKF Diagnostics Positive
Creo Medical Group Neutral

Summary

EKF Diagnostics beats Creo Medical Group on 8 of the 15 factors compared between the two stocks.

How does Creo Medical Group compare to Intelligent Ultrasound Group?

Creo Medical Group (LON:CREO) and Intelligent Ultrasound Group (LON:IUG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

In the previous week, Creo Medical Group's average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company Overall Sentiment
Creo Medical Group Neutral
Intelligent Ultrasound Group Neutral

Creo Medical Group has a net margin of 88.33% compared to Intelligent Ultrasound Group's net margin of -23.11%. Creo Medical Group's return on equity of 9.56% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

Creo Medical Group has a beta of 1.6246382, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are held by institutional investors. 6.4% of Creo Medical Group shares are held by insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Intelligent Ultrasound Group has higher revenue and earnings than Creo Medical Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.93-£25.04M£1.0013.50
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

Summary

Creo Medical Group and Intelligent Ultrasound Group tied by winning 5 of the 10 factors compared between the two stocks.

How does Creo Medical Group compare to Novacyt?

Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 10.7% of Novacyt shares are owned by institutional investors. 6.4% of Creo Medical Group shares are owned by company insiders. Comparatively, 0.7% of Novacyt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Creo Medical Group has a beta of 1.6246382, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, suggesting that its stock price is 11% more volatile than the broader market.

Creo Medical Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M10.93-£25.04M£1.0013.50
Novacyt£20.03M1.25-£36.80M-£32.00N/A

In the previous week, Novacyt's average media sentiment score of 0.99 beat Creo Medical Group's score of 0.00 indicating that Novacyt is being referred to more favorably in the news media.

Company Overall Sentiment
Creo Medical Group Neutral
Novacyt Positive

Creo Medical Group has a net margin of 88.33% compared to Novacyt's net margin of -135.96%. Creo Medical Group's return on equity of 9.56% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Novacyt -135.96%-121.30%-27.98%

Summary

Creo Medical Group beats Novacyt on 10 of the 12 factors compared between the two stocks.

How does Creo Medical Group compare to Inspiration Healthcare Group?

Inspiration Healthcare Group (LON:IHC) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Creo Medical Group has a net margin of 88.33% compared to Inspiration Healthcare Group's net margin of -2.19%. Creo Medical Group's return on equity of 9.56% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Inspiration Healthcare Group-2.19% -6.49% -3.47%
Creo Medical Group 88.33%9.56%-20.09%

7.4% of Inspiration Healthcare Group shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 8.4% of Inspiration Healthcare Group shares are held by insiders. Comparatively, 6.4% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Inspiration Healthcare Group has higher revenue and earnings than Creo Medical Group. Inspiration Healthcare Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspiration Healthcare Group£45.20M0.46-£12.20M-£13.65N/A
Creo Medical Group£6M10.93-£25.04M£1.0013.50

Inspiration Healthcare Group has a beta of 0.867, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.6246382, meaning that its stock price is 62% more volatile than the broader market.

In the previous week, Inspiration Healthcare Group had 2 more articles in the media than Creo Medical Group. MarketBeat recorded 2 mentions for Inspiration Healthcare Group and 0 mentions for Creo Medical Group. Inspiration Healthcare Group's average media sentiment score of 0.70 beat Creo Medical Group's score of 0.00 indicating that Inspiration Healthcare Group is being referred to more favorably in the media.

Company Overall Sentiment
Inspiration Healthcare Group Positive
Creo Medical Group Neutral

Summary

Creo Medical Group beats Inspiration Healthcare Group on 7 of the 13 factors compared between the two stocks.

Get Creo Medical Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CREO vs. The Competition

Export
MetricCreo Medical GroupMedical Devices IndustryMedical SectorLON Exchange
Market Cap£65.58M£2.10B£6.46B£2.80B
Dividend YieldN/A2.67%2.68%6.16%
P/E Ratio13.5014.6220.73367.11
Price / Sales10.93124.01577.0486,377.90
Price / Cash2.4315.9944.2027.85
Price / Book1.034.3910.707.95
Net Income-£25.04M£144.75M£3.57B£5.89B
7 Day Performance1.28%-1.42%0.56%1.38%
1 Month Performance14.89%-2.33%3.57%1.63%
1 Year Performance1.88%-3.33%28.49%73.73%

Creo Medical Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CREO
Creo Medical Group
N/AGBX 13.50
-1.8%		GBX 40
+196.3%		+2.0%£65.58M£6M13.50279
NIOX
NIOX Group
N/AGBX 58
+1.0%		GBX 86
+48.3%		-11.6%£244.10M£48.70M35.3792
EKF
EKF Diagnostics
2.6925 of 5 stars		GBX 25
-2.0%		GBX 35
+40.0%		+4.2%£107.63M£51.56M53.19356
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
NCYT
Novacyt
N/AGBX 36.88
+6.6%		N/A-17.7%£26.72M£20.03MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CREO) was last updated on 6/18/2026 by MarketBeat.com Staff.
From Our Partners
Hopeless About Retirement? Hopeless and Helpless Aren’t the Same Thing
Your retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's ...
Golden Portfolio | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
A 3M Oz. Historical Gold Resource And A Market That Hasn't Caught Up
One Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...
Wall Street Logic | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel